AptarGroup (ATR) stock
ATR · AptarGroup Inc. · NYSE
What is the latest news on ATR stock?
ATR fell 0.17% to $140.06 on Nov 20, 2026. No ATR story in the last two days; the most recent is below.
4 - APTARGROUP, INC. (0000896622) (Issuer)
All ATR newsWho owns the most ATR stock?
BlackRock, Inc. was the largest reported holder of ATR at the end of Q2 2026, with 6,137,894 shares worth $768.5 million. Next came State Farm Mutual Automobile Insurance Co ($594.0 million) and Vanguard Portfolio Management LLC ($455.6 million). In all, 553 institutions reported $7.7 billion of ATR in their 13F filings.
All ATR fund holdersAre insiders buying or selling ATR?
Insiders are selling. In the last 90 days 3 insiders sold $884K of ATR in trades reported on Form 4. The latest: Marc Prieur sold $284K, reported on Nov 3, 2026.
ATR insider tradesFinancial highlights
Full financials- Revenue, TTM
- $3.99B
- Revenue growth
- +9.0%
- Net income, TTM
- $267.19M
- Net margin
- 6.7%
- Free cash flow, TTM
- $294.69M
- Cash
- $204.18M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- INSIDERDirector Fotiades George L gifted 1,600 shares, decreasing direct ownership by 25% to 4,846 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSegment President Prieur Marc sold $283,974 worth of shares (2,000 units at $141.99), decreasing direct ownership by 13% to 13,823 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- SECSEC Form 10-Q filed by AptarGroup Inc.10-Q - APTARGROUP, INC. (0000896622) (Filer)
- PRAptar Reports Third Quarter 2026 ResultsAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results for the period ended September 30, 2026, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029508419/en/Aptar Reports Third Quarter 2026 Results Third Quarter 2026 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% and core sales increased 5% Reported net income was $33
- SECSEC Form 8-K filed by AptarGroup Inc.8-K - APTARGROUP, INC. (0000896622) (Filer)
- PRAptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System SelectionJoint system-level testing combines Stevanato Group glass syringes with Aptar Pharma elastomer components to provide key data earlier in development and help inform packaging decisions for sensitive biologics and other injectable therapies Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Stevanato Group to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapies. The work builds on Aptar Pharma's integrated system-level framework
- PRAptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug DeliveryAcquisition is expected to accelerate development and commercialization of Kolibri™ and expand Aptar Pharma’s respiratory drug delivery platform Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the strategic acquisition of PULMOTREE, a Munich, Germany-based life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs. The acquisition is expected to accelerate the development, industrialization and commercialization of PULMOTREE’s Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/
- PRAptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma BusinessAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022738970/en/Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business Maes joins Aptar from Amcor, where she currently leads its global Flexibles Pharma and Medical packaging business, spanning North America, Latin America, EMEA and Asia. During her career at Amcor, she has held senior leadership roles across pharma,
- PRAptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine DevelopersMilestone strengthens Aptar Pharma’s support for intranasal vaccine development from clinical studies through commercialization Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax® intranasal delivery device and accompanying Spray Divider have been CE marked under the EU Medical Device Regulation (MDR), indicating that they meet the European general safety and performance requirements for medical devices. This milestone expands Aptar Pharma’s support for customers developing innovative intranasal vaccine products. This press release features multimedia.
- ANALYSTDeutsche Bank initiated coverage on AptarGroup with a new price targetDeutsche Bank initiated coverage of AptarGroup with a rating of Buy and set a new price target of $150.00
- SECAptarGroup Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - APTARGROUP, INC. (0000896622) (Filer)
- PRAptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug DeliveryGoal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelines AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH) to advance the science of nose-to-brain (N2B) drug delivery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914424839/en/Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Mod
- INSIDERNew insider Ackerman Daniel claimed ownership of 32,779 shares (SEC Form 3)3 - APTARGROUP, INC. (0000896622) (Issuer)
- SECAptarGroup Inc. filed SEC Form 8-K: Leadership Update8-K - APTARGROUP, INC. (0000896622) (Filer)
- INSIDERChief Human Resources Officer Vinczeller Shiela sold $99,733 worth of shares (765 units at $130.37), decreasing direct ownership by 3% to 26,313 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERPresident and CEO Touya Gael was granted 2,637 shares, increasing direct ownership by 9% to 31,739 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- SECAptarGroup Inc. filed SEC Form 8-K: Leadership Update8-K - APTARGROUP, INC. (0000896622) (Filer)
- INSIDERSegment Pres., CEO Designate Touya Gael sold $500,276 worth of shares (3,740 units at $133.76), decreasing direct ownership by 11% to 29,102 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AptarGroup Inc.SCHEDULE 13G/A - APTARGROUP, INC. (0000896622) (Subject)
- INSIDERSegment President Prieur Marc sold $476,897 worth of shares (3,500 units at $136.26), decreasing direct ownership by 18% to 15,823 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERPresident and CEO Tanda Stephan B. exercised 9,838 shares at a strike of $74.79 and sold $1,339,588 worth of shares (9,838 units at $136.16) (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSegment President Tlili Hedi sold $1,195,290 worth of shares (8,854 units at $135.00), decreasing direct ownership by 37% to 15,379 units (SEC Form 4)4 - APTARGROUP, INC. (0000896622) (Issuer)
- SECSEC Form 10-Q filed by AptarGroup Inc.10-Q - APTARGROUP, INC. (0000896622) (Filer)
- SECAptarGroup Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - APTARGROUP, INC. (0000896622) (Filer)
- PRAptar Reports Second Quarter 2026 ResultsAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following second quarter results for the period ended June 30, 2026, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730133160/en/Aptar Reports Second Quarter 2026 Results Second Quarter 2026 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% to over $1 billion for the first time, and core sales increa
ATR rankings
- Insider6(33%)
- SEC Filings5(28%)
- Other4(22%)
- Analyst1(6%)
- Leadership1(6%)
- M&A1(6%)
AptarGroup Inc. (ATR) is a Plastic Products company listed on NYSE. In the last 30 days Quantisnow tracked 7 wire items for ATR, including 2 SEC filings, 2 insider trades and 1 M&A update. The most recent was published Nov 6, 2026.
ATR FAQ
10 questionsWhat does AptarGroup Inc. do?
AptarGroup, Inc. provides a range of packaging, dispensing, and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active packaging products...What is ATR revenue?
AptarGroup Inc. (ATR) reported $3.99B of revenue for the twelve months ended Sep 30, 2026. That is up 9.0% from the year before. Revenue for fiscal 2025 was $3.78B.Is ATR profitable?
Yes. AptarGroup Inc. earned $267.19M in net income for the twelve months ended Sep 30, 2026, a net margin of 6.7%.How much cash and debt does ATR have?
AptarGroup Inc. reported $204.18M in cash and cash equivalents and $1.25B of debt on its most recent balance sheet in SEC filings.Where does ATR stock trade?
AptarGroup Inc. (ATR) is listed on NYSE.What sector and industry is ATR in?
AptarGroup Inc. operates in the Industrials sector, Plastic Products industry.Does ATR pay a dividend?
ATR's most recent ex-dividend date was 2026-11-12 with a cash dividend of $0.50 per share. No future ex-date is on file yet.What are analysts saying about ATR?
Across the last 8 analyst actions on AptarGroup Inc., there were 2 upgrades and 3 downgrades. The most recent action was from Deutsche Bank: Buy with a $150.00 price target on 2026-10-07. Recent price targets range from $133.00 to $220.00.What companies are similar to ATR?
Notable peers in the same industry include SON (Sonoco Products Company), SLGN (Silgan Holdings Inc.), CCK (Crown Holdings Inc.), WST (West Pharmaceutical Services Inc.), OI (O-I Glass Inc.). Compare ATR side-by-side with any of them on Quantisnow.How can I track ATR on Quantisnow?
Quantisnow aggregates AptarGroup Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATR to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change